Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $70.4 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 20.59% year-over-year to $70.4 million in Q1 2026; TTM through Mar 2026 was $70.4 million, a 20.59% decrease from a year earlier, with the FY2025 full-year figure at $72.8 million, down 21.89% from the prior year.
• Total Liabilities fell to $70.4 million in Q1 2026 per ZNTL's latest filing, from $72.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $114.3 million in Q4 2023 and bottomed at $70.4 million in Q1 2026.
• The 5-year median for Total Liabilities is $96.3 million (2024), against an average of $93.6 million.
• Across the five-year window, Total Liabilities soared 161.42% in 2022 and dropped 29.23% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $105.3 million in 2022, then climbed by 8.56% to $114.3 million in 2023, then slipped by 18.5% to $93.2 million in 2024, then declined by 21.89% to $72.8 million in 2025, then decreased by 3.27% to $70.4 million in 2026.
• Per Business Quant, the three latest ZNTL Total Liabilities figures stand at $70.4 million (Q1 2026), $72.8 million (Q4 2025), and $74.4 million (Q3 2025).